ROSVIVO THERAPEUTICS
RosVivo Therapeutics is a biotechnology company it develops microRNA-based therapeutics for type 2 diabetes, obesity, fatty liver disease. RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. Discovery research conducted by Dr. Seungil Ro’s laboratory recently identified key miRNAs responsible for the onset and development of Type 2 Diabetes (T2D). Preclinical studies show depletion of these key miRNAs lead to the development of not only T2D, but also obesity, fatty acid liver disease, hyperlipidemia, and gastroparesis. Remarkably, restoration of these miRNAs reverses these disease states.
ROSVIVO THERAPEUTICS
Industry:
Biotechnology Diabetes Health Care Health Diagnostics Therapeutics
Founded:
2021-01-01
Address:
Reno, Nevada, United States
Country:
United States
Website Url:
http://www.rosvivo.com
Status:
Closed
Contact:
(775) 409-6007
Email Addresses:
[email protected]
Total Funding:
5.45 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Official Site Inspections
http://www.rosvivo.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "RosVivo Therapeutics"
RosVivo Therapeutics - Crunchbase Company Profile & Funding
RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. Discovery research conducted by Dr. Seungil Ro’s …See details»
RosVivo Therapeutics - LinkedIn
Novel miRNA therapeutics for anti-obesity and diabetes. Developing first-in-class micro RNA therpeutics with the potential to treat obesity, diabetes, Nonalcoholic steatohepatitis (or …See details»
RosVivo Therapeutics Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, cap tables, investors, and executives for RosVivo Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
RosVivo Therapeutics - VentureRadar
RosVivo Therapeutics targets diseases with breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. The company's lead candidate RSVI-301 effectively …See details»
Sandra Poudrier - Co-Founder, Chief Operations Officer at RosVivo ...
Sandra has 25 experience in biotech in all aspects of product lifecycles from basic research to scale up, cGMP manufacturing, product validation, and post marketing product support. She …See details»
RosVivo Therapeutics - Products, Competitors, Financials, …
RosVivo Therapeutics specializes in pharmaceutical treatments within the biotechnology sector. The company focuses on developing therapies for metabolic diseases using microRNA …See details»
RosVivo Therapeutics - Contacts, Employees, Board Members
RosVivo Therapeutics has 3 current employee profiles, including Co Founder/Director Of Operations Sandra Poudrier. RosVivo Therapeutics is a biotechnology company it develops …See details»
Nexturn Bio acquires RosVivo Therapeutics - Crunchbase
May 6, 2021 · Acquired Organization: RosVivo Therapeutics RosVivo Therapeutics is a biotechnology company it develops microRNA-based therapeutics for type 2 diabetes, obesity, …See details»
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
May 30, 2021 · Nexturn Bio Inc. decided to invest in RosVivo and its miRNA technology through due diligence and valuation by industry-leading law firms, patent corporations, strategy …See details»
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
Jun 1, 2021 · Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc. (“Rosvivo”), an American …See details»
RosVivo Therapeutics, Inc. signed a Material Transfer Agreement …
Feb 22, 2022 · RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate that can fundamentally treat diabetes by restoring the function of beta cells that secrete insulin, the …See details»
RSVI 302 - AdisInsight - Springer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. 04 Oct 2022 RSVI 302 is available for licensing as of 04 Oct 2022. …See details»
RosVivo signed MTA for diabetes treatment with Eli Lilly and …
Feb 23, 2022 · RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate that can fundamentally treat diabetes by restoring the function of beta cells that secrete insulin, the …See details»
RSVI-302 - Drug Targets, Indications, Patents - Synapse - Patsnap
RSVI-302: a RNA interference Drug, Initially developed by The University of Nevada, Reno, Now, its global highest R&D status is Preclinical, Mechanism: RNA interference, Therapeutic Areas: …See details»
Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
SEOUL, South Korea, May 30, 2021 /PRNewswire/ -- Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on May 26th that it had acquired a 50% stake in RosVivo …See details»
Eli Lilly, RosVivo Therapeutics ink pact for diabetes treatment
Feb 23, 2022 · Seoul: RosVivo Therapeutics, Inc. has announced that the company has signed a Material Transfer Agreement (MTA) with Eli Lilly and Company for commercial development of …See details»
RSVI 301 - AdisInsight - Springer
Jun 28, 2023 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.See details»
RSVI-306 - Drug Targets, Indications, Patents - Synapse - Patsnap
Understand key drug designations in just a few clicks with Synapse. RSVI-306, Initially developed by RosVivo Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Therapeutic …See details»
RSVI-304 - Drug Targets, Indications, Patents - Synapse
Now, its global highest R&D status is Preclinical, Therapeutic Areas: Endocrinology and Metabolic Disease, Active Indication: Diabetes Mellitus, Type 2, Active Org.: RosVivo Therapeutics, Inc..See details»
RSVI-305 - Drug Targets, Indications, Patents - Synapse
RSVI-305: a RNA interference Drug, Initially developed by RosVivo Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Mechanism: RNA interference, Therapeutic Areas: …See details»